|Application ||IHC-P, IF, FC|
|Isotype||Rabbit / IgG, kappa|
|Calculated MW||63747 Da|
|Other Names||CD30L receptor, Cytokine receptor CD30, Ki-1 antigen, Lymphocyte activation antigen CD30, Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)|
|Application Note||Flow Cytometry (0.5-1ug/million cells); Immunofluorescence (1-2ug/ml); ,Immunohistology (Formalin-fixed) (0.5-1ug/ml for 30 minutes at RT),(Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris with 1mM EDTA, pH 8.0, for 10-20 min followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined.|
|Format||200ug/ml of Ab purified by Protein A Column. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||Anti-CD30 / TNFRSF8 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF- kappa-B.|
|Cellular Location||Isoform 1: Cell membrane; Single-pass type I membrane protein|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkin s disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This antibody distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.